Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

EP: 1.Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment

EP: 2.Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

EP: 3.Clinical Scenario 1: 76-Year-Old Man With Newly Diagnosed MDS With Symptomatic Anemia, RS Positive

EP: 4.Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

EP: 5.First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting

EP: 6.Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring

EP: 7.Second-Line LR- MDS Setting: Treatment Options and Considerations

EP: 8.Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative

EP: 9.Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels

EP: 10.First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient

EP: 11.Imetelstat and IMerge Trial Review

Now Viewing

EP: 12.Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

EP: 13.The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs

Video content above is prompted by the following:

• Are there any novel agents and/or combination strategies in LR-MDS that may change our treatment landscape for LR-MDS? (Potential suggestions below, feel free to comment on any additional studies.)

Luspatercept vs epoetin alfa NTD LR-MDS: ELEMENT-MDS trial.

Jonasova A, et al. Luspatercept plus erythropoietin in LR-MDS. EHA 2024, abstract P1886.

Komrokji RS, et al. Luspatercept plus ESA combinations in LR-MDS. Blood Adv. 2023.

Díez Campelo M, et al. Phase 2 study, elritercept (KER-050). EHA 2024, abstract S183.

Mittelman M, et al. Phase 3, roxadustat: Matterhorn Study. ASH 2023 abstract.

Sallman DA et al. Phase 1b/2 study evaluating canakinumab for 2L treatment in patients with LR-MDS. ASH 2023, abstract 620.